Cynata Therapeutics (OTCMKTS:CYYNF) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Tuesday, Zacks.com reports.
According to Zacks, “Cynata Therapeutics Ltd is a stem cell and regenerative medicine company. It is developing a therapeutic stem cell platform Cymerus(TM), a mesenchymal stem cell technology for human therapeutic use. Cynata Therapeutics Ltd is based in Armadale, Australia. “
Shares of OTCMKTS:CYYNF remained flat at $$0.95 during midday trading on Tuesday. The stock had a trading volume of 500 shares, compared to its average volume of 25. Cynata Therapeutics has a fifty-two week low of $0.75 and a fifty-two week high of $1.12.
Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand name for human therapeutic use in Australia. Its lead therapeutic product candidate is CYP-001, which is in Phase I clinical trial for the treatment of graft versus host disease.
Recommended Story: What is an Initial Public Offering (IPO)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cynata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cynata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.